The Effect of *Bifidobacterium Bifidum* Supernatant and Cell Mass on the Proliferation Potential of Rat Bone Marrow-Derived Stromal Cells

Mostafa Saberian1, MSc; Elham Shahidi Delshad2, MSc; Masoud Habibi3, MD, PhD

1Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences. Tehran, Iran; 2Shahid Rajaei Cardiovascular Research Center, Iran University of Medical Sciences, Tehran, Iran; 3Department of Genetics, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran

Correspondence: Mostafa Saberian, MSc; No. 44, Hojjat Doust St, Naderi St, Keshavarz Blvd., Postal code: 16538-77168, Tehran, Iran
Tel: +98 21 76701044
Fax: +98 21 88955742
Email: mostafasaberian@gmail.com
Received: 04 August 2018
Revised: 16 September 2018
Accepted: 30 September 2018

**Abstract**

**Background:** Mesenchymal stem cells (MSCs) are widely used to treat various diseases, however, their proliferative potential reduces after a number of passages. It has been shown that some probiotics such as *Bifidobacterium bifidum* (*B. bifidum*) affect the proliferation of various cell lineages. The present study aimed to investigate the effect of *B. bifidum* on the proliferation of rat bone marrow stromal cells (rBMSCs) and to develop a method for compensating their proliferation reduction after some passages.

**Methods:** The present experimental study was conducted at Tehran University of Medical Sciences, Tehran, Iran, in 2017. The stromal cells were isolated from rBMSCs and their mesenchymal properties were confirmed by osteogenic and adipogenic differentiation media and staining. *B. bifidum* was cultured and the *B. bifidum* supernatant (BS) and bacterial cell mass (BCM) were extracted. The rBMSCs were treated with different concentrations of BS and BCM. The MTT assay was performed to measure the number of viable cells in the culture. Cell proliferation was analyzed using the paired-sample *t* test.

**Results:** Cell proliferation increased as the concentration of bacteria was increased logarithmically (0, 0.1, 0.3, 0.9, 3, 9, 30 μL/mL). In comparison with BS, cells treated with BCM showed increased cell proliferation at lower concentrations. This effect was caused by removing the “de Man, Rogosa, and Sharpe” (MRS) broth medium from the BCM culture. The optimal concentration of bacteria with the most significant effect on rBMSCs proliferation was determined.

**Conclusion:** A significant increase in the proliferation of stromal cells was observed; confirming the stimulatory potential of probiotics (*B. bifidum*) on various cells. The use of products containing probiotic bacteria can increase the proliferation potential of BMSCs.

Please cite this article as: Saberian M, Shahidi Delshad E, Habibi M. The Effect of *Bifidobacterium Bifidum* Supernatant and Cell Mass on the Proliferation Potential of Rat Bone Marrow-Derived Stromal Cells. Iran J Med Sci. 2020;45(4):269-276. doi: 10.30476/ijms.2019.45772.

**Keywords**

- *Bifidobacterium bifidum*
- Mesenchymal stromal cells
- Cell proliferation
- Probiotics

**Introduction**

Today, there has been a growing consumption of products containing probiotic bacteria to treat various diseases. This group of bacteria has several benefits such as modulating...
gastrointestinal microorganisms. Studies have shown the health benefits of specific probiotic strains of Lactobacillus, Bifidobacterium, Saccharomyces, Enterococcus, Streptococcus, Pediococcus, Leuconostoc, Bacillus, Escherichia coli. Although the activating mechanism of many probiotics has been identified, there are ongoing research studies to understand other mechanisms and their effects on various diseases. For instance, the effect of probiotics on diarrhea, cholesterol absorption, and lactose sensitivity has been demonstrated.

Several studies have addressed the effect of probiotics on diseases such as immune system disorders and cancer. A previous study has shown that oral administration of probiotics could be a mitogen for lymphocytes proliferation and increase serum levels of IgG, IgM, and secretory IgA. Studies have been conducted to investigate the effect of probiotics on the proliferation of various cell lineages. Some studies have shown the potential of probiotics on reducing the proliferation of cancer cells (especially gastrointestinal carcinoma) and some others have used probiotic agents as adjuvants to control gastrointestinal cancer. A previous study showed that the supernatants of Lactobacillus acidophilus (LS) stimulated the proliferation of macrophages and lymphocytes by increasing chemotaxis and angiogenesis properties. The effect of LS on embryonic stem cells and on the proliferation of rat bone marrow stromal cells (rBMSCs) has also been demonstrated. Additionally, the role of probiotics in cell differentiation has been studied.

Stem cells, particularly mesenchymal stem cells (MSCs), are widely used to treat various diseases such as cancer. Recent advancement in stem cell transplantation has resulted in increased effectiveness of such treatments. However, one of the main limitations of MSCs is the reduction of their proliferative potential after numerous passages whereby cells tend to differentiate. Consequently, it is important to find methods to increase the proliferation rate of these cells. It has been shown that Lactobacillus stimulates the proliferation of macrophages and lymphocytes, and it has some common metabolic properties with Bifidobacterium. Hence, the present study aimed to investigate the effect of Bifidobacterium bifidum (B. bifidum) on rBMSCs and to develop a method for compensating for their proliferation reduction after some passages.

**Materials and Methods**

The present experimental study was conducted at Tehran University of Medical Sciences, Tehran, Iran.

**Preparation of Bacterial Supernatant and Extract**

B. bifidum strain (ATCC: 29521) was obtained from the Iran Research Organization for Science and Technology (IROST), Tehran, Iran, in 2017. The bacteria were cultured in MRS broth (pH value 5.5, Millipore-110661) with 0.05% L-cysteine (Sigma, 24850236) at 37 °C for 48 hours under microaerophilic conditions. The suspension was centrifuged three times at 10,000 ×g at 4 °C until the bacterial count reached 2x10^8 CFU, using the pour plate method. The supernatant was separated and filtered using a 0.2 µm microfilter. Then, the B. bifidum supernatant (BS) was frozen and stored for later use. To isolate the bacterial extract, the sediment mass was harvested after each centrifugation.

**Isolation of Rat Bone Marrow Stromal Cells**

A male rat (6-8 weeks old, weighing 300 grams) was obtained from the Pasteur Institute, Tehran, Iran. In accordance with the University’s code of ethics (number: IR.TUMS.REC.1394.533) the rat was sacrificed by CO₂ asphyxiation. The tibia was dissected under sterile conditions and the surrounding muscle tissue was completely removed. The tibia was cut at both ends and the bone marrow stromal tissue was flushed out with a mixture of Dulbecco’s modified eagle’s medium (DMEM), 2 mM Glutamax, 1 mM L-glutamine, 10% fetal bovine serum (FBS), 1% penicillin/streptomycin, nystatin and amphotericin B, and 1% non-essential amino acids (all from Gibco, Carlsbad, CA). Finally, the cells were filtered through a 70 mm diameter filter (Hawach Scientific Co., China) to remove debris.

**Primary Stromal Cell Culture**

Cell viability was determined using trypan blue dye (Merck, Millipore, 23850, Germany). A Petri dish containing the complete culture medium, as mentioned above, was used to seed 25x10⁵ cells and was subsequently incubated under standard conditions with 5% CO₂ at 37 °C for 3 hours. Then, the unattached cells were removed and the medium was replaced with the fresh culture medium. After 8 hours, the medium was replaced again with 10 mL of fresh culture medium. This process was repeated every 8 hours for 72 hours, after which the remaining attached cells were washed with phosphate-buffered saline (PAA Laboratories GmbH, Austria); the medium was replaced every 3 days. After 4 weeks, when the culture
reached about 80% confluency, it was incubated for 2 minutes with 25% trypsin in 1 mM EDTA (L11-001, PAA Laboratories Inc, Austria). After trypsin neutralization, the cells were seeded in 25 cm² flasks.

Cell Differentiation into Osteogenic and Adipogenic Lineages

A total of 5x10⁴ cells were seeded in 6-well plates containing DMEM, 15% FBS, and 1% penicillin/streptomycin. The cultures were divided into three groups. The culture medium of the first group included rBMSCs without any B. bifidum contents. The second group included rBMSCs in the differentiation medium together with BS and the third group with B. bifidum bacterial cell mass (BCM). These cultures were incubated under standard conditions with 5% CO₂ at 37 °C for 7 days. The cells were then cultured in an osteogenic or an adipogenic differentiation defined medium and incubated for 21 days during which the medium was replaced every 3 days.

Each milliliter of the osteogenic culture medium composed of DMEM, 50 mg/mL ascorbic acid 2-phosphate, 10 nM dexamethasone, and 10 nM β-glycerol phosphate, all produced by Sigma Aldrich, US. Finally, the cells were fixed for 10 minutes in 10% formalin, stained with Alizarin red for 15 minutes at room temperature, and observed under a light microscope (Olympus, Germany). Similarly, each milliliter of adipogenic culture medium composed of DMEM supplemented with 15% FBS, 50 mg/mL indomethacin, and 100 M dexamethasone. To determine adipocytes differentiation, the cells were stained with 0.5% Oil red-O for 15 minutes and then observed under a light microscope.

Cell Proliferation Assay

The cell viability was determined using the [3-(4,5 dimethylthiazol-2-yl)-1,5 diphenyltetrazolium bromide] MTT colorimetric assay. The principle of the MTT assay is the ability of the living cells to convert tetrazulium to formazan. In brief, 5x10³ cells were seeded in a 96-well microplate. The cells were then treated for 14 days with the medium from each of the two groups containing BS or BCM in different concentrations (0, 0.1, 0.3, 0.9, 3, 9, and 30 µL/mL of supplemented DMEM). During this period, the medium was replaced every 3 days. Besides, a control group (standard) was added, which included the cells with culture medium without BS and BCM.

The medium was replaced with 15% MTT solution (Atocel, Austria) in PBS (5 mg/ml) and incubated at 37 °C for 2 hours. The solution in each well was replaced with DMSO and shaken in a dark chamber for 15 minutes. Finally, the optical density for each well was measured using a plate reader at the wavelength of 570 nm and a reference wavelength of 630 nm. The number of cells was determined using a standard curve. The tests were repeated six times for each sample (n=6).

Statistical Analyses

Distribution of the data was evaluated using the Kolmogorov-Smirnov test (one-sample and pair-sample tests). The data were expressed as mean±SD and analyzed using the paired-sample t test. P<0.05 was considered statistically significant. The SigmaPlot software (version 12.0) was used for the graphical presentation of the data.

Results

Cell Differentiation into Osteogenic and Adipogenic Lineages

After the preparation of the primary cell culture, the cells were used in the second passage (figure 1a). The rBMSCs were cultured in osteogenic and adipogenic media, after which the cells differentiated into osteoblasts and adipocytes. Figure 1 (b, c) shows the cells subjected to osteogenic differentiation.
for 14 days and then stained with Alizarin red. Calcium deposition was detected, indicating their differentiation potential (figure 1b). The rBMSCs cells cultured in an adipogenic differentiation medium (stained by Oil red-O) differentiated into adipocytes (figure 1c). This differentiation was considered a key feature of the rBMSCs, especially the MSCs. After 14 days of rBMSCs treatment with BS and BCM, using the exact same protocol, the staining process was performed with Alizarin red and Oil red-O. Figure 2 shows a comparison between the test sample and the negative control.

**Cell Proliferation Assay**

The viability of the cells was determined using the MTT assay after treating the rBMSCs with different quantities of BS or BCM. The optical density for each well, measured with a plate reader, was converted to the number of cells using the standard curve (tables 1 and 2). In parallel, the viability of the cells was determined in cells treated with MRS broth medium with similar concentrations as BS and BCM. The results between the groups were analyzed and compared using the paired-sample t test. The results showed that changes in cell proliferation in the MRS broth medium were less than changes in BS and BCM. The cell proliferation at low concentrations of the MRS broth (0.1, 0.3, and 0.9 μL/mL) was similar to the control group. However, cell viability reduced at higher concentrations.

The results of the MTT assay showed

![Figure 2](image-url)

**Table 1:** The number of cells treated with *Bifidobacterium bifidum* supernatant in different concentrations

| Bacterial supernatant concentration (μL/mL) | The number of cells | mean±SD       | P value |
|-------------------------------------------|---------------------|---------------|---------|
| 0.1                                       | 12686 12309 12792 12786 12260 12680 12585.5±238.44 | 0.283         |
| 0.3                                       | 12663 12483 12852 12511 12917 12711 12689.9±175.40 | 0.271         |
| 0.9                                       | 12715 12905 12823 12688 12694 12992 12802.83±125.99 | 0.235         |
| 3.0                                       | 13336 13557 13244 13501 13218 13423 13379.83±137.47 | 0.186         |
| 9.0                                       | 14274 14841 14564 14510 14331 14404 14487.3±204.14 | 0.011         |
| 30.0                                      | 13780 14109 13914 14278 13899 13662 13940.3±222.73 | 0.046         |

**Table 2:** The number of cells treated with bacterial cell mass in different concentrations

| Bacterial cell mass concentration (μL/mL) | The number of cells | mean±SD       | P value |
|------------------------------------------|---------------------|---------------|---------|
| 0.1                                      | 12686 12309 12792 12786 12260 12680 12585.5±238.44 | 0.283         |
| 0.3                                      | 12761 12585 12957 12611 12812 12611 12722.8±147.14 | 0.266         |
| 0.9                                      | 13105 12905 12823 12288 12914 12992 13004.5±285.65 | 0.249         |
| 3.0                                      | 13801 13757 14244 13901 14218 13723 13940.67±232.85 | 0.040         |
| 9.0                                      | 14450 14731 14812 14596 14664 14804 14673.17±138.73 | 0.036         |
| 30.0                                     | 12780 13109 12914 13278 12899 12662 12940.3±222.73 | 0.241         |
that treatment with BS and BCM induced the proliferation of BMSCs (figures 3 and 4). An increase in cell proliferation with the BS treatment started at 0.9 μL/mL concentration and reached its peak at 9 μL/mL. It was also observed that cell proliferation reduced at higher concentrations (30 μL/mL). An increase in BMSCs proliferation with BCM treatment started at 0.3 μL/mL concentration and peaked at 9 μL/mL. The outcomes of the treatment were compared with the results of the negative control group. The results obtained from the treatment of rBMSCs with B.bifidum showed that the maximum cell proliferation was at 9 μL/mL concentration. At this concentration, there was a significant increase in cells treated with BS (P=0.011) and BCM (P=0.036). It was observed that both the BS and BCM had the maximum effect at this concentration (tables 1 and 2). Comparing each concentration with the negative control showed that the highest level of significance was at 9 μL/mL concentration, but the effect in other quantities of BS or BCM was also significant. For instance, treatment with BS at 30 μL/mL concentration (P=0.046) and treatment with BCM at 3 μL/mL concentration (P=0.040).

Discussion

The results showed a significant increase in the proliferation of stromal cells, which confirmed the stimulatory potential of probiotics (Lactobacillus and Bifidobacterium) on various cells. Several studies have shown the effect of probiotics in limiting the proliferation of neoplastic cells, especially in gastrointestinal tract cancers. On the other hand, some other studies have confirmed the anti-apoptotic role of Bifidobacterium in the intestinal epithelial cells. In contrast with the results of a previous study on the effects of Lactobacillus,13 we found a significant increase in cell proliferation with B. bifidum at 9 μL/mL concentration. The increase in cell proliferation in the BCM culture started at lower concentrations (0.3 μL/mL) while the onset of cell proliferation in the BS culture was at 0.9 μL/mL. The results also showed a decrease in cell proliferation in the BCM and BS cultures at higher concentrations (30 μL/mL); indicating increased effectiveness at lower concentrations.

To understand the mechanism responsible for increased cell proliferation, we used BCM as a supernatant while previous studies used probiotics.13, 31-33 In addition, B. bifidum was used in the present study to measure cell proliferation whereas previous studies used Lactobacillus. Nonetheless, the results are comparable since both bacteria exhibited similar cell proliferation characteristics. It was observed that both B. bifidum and Lactobacillus had the potential to increase stromal cell proliferation. Although Lactobacillus...
was more effective at lower concentrations, the increase in both bacteria was somewhat similar. Therefore, we believe that these bacteria share common characteristics. Further research to confirm this finding is recommended.

The MRS broth was a suitable medium for the cultivation of Lactobacillus and Bifidobacterium. However, similar to a previous study, we observed an inhibitory effect on cell viability at high concentrations of MRS broth. Since the amount of MRS broth medium reached the lowest level in the BCM group, the inhibitory effect of the culture medium was reduced. If the bacterial culture medium is removed, it is anticipated that cell proliferation would be slightly higher than BCM. Therefore, using an alternative method (freeze-drying) may reduce the inhibitory effects of the bacterial medium. By comparing the results from cell treatment with BS and BCM, the most effective inhibitory role of the bacterial medium was in the use of supernatant. Note that during the process of BCM preparation, a maximum amount of MRS broth media was eliminated by centrifugation.

A previous study on Lactobacillus indicated that the substances secreted in the supernatant had primarily overcome the inhibitory effect of MRS broth. The results of the present study suggest that B. bifidum can also partially overcome the inhibitory effect of the bacterial medium. In addition, there was significant cell proliferation in some concentrations of BS. Therefore, it is most likely that there were common substances in Lactobacillus and Bifidobacterium supernatants that stimulated the proliferation of cells in multiple passages. In the absence of these substances, cell proliferation gradually decreased after some passages. These findings confirm the presence of substances secreted by some probiotic bacteria that can be used as stimulants for the proliferation of stromal cells. Therefore, the use of B. bifidum supernatant in an optimum concentration can be beneficial and an effective factor in the proliferation of cells such as rBMSCs.

Methodology and Results

Conclusion

The use of B. bifidum is a low-cost and accessible method to increase the proliferation potential of BMSCs. B. bifidum can be easily cultivated, propagated, and is a suitable culture medium. Further studies are required to complement our initial findings and to provide detailed information on the effective substances causing cell proliferation by probiotic bacteria.

Acknowledgment

The present study was financially supported by a grant from Tehran University of Medical Sciences and Health Services, Tehran, Iran (grant number: 94-01-31-27049). The authors would like to thank the University Vice-Chancellor for supporting the research.

Conflict of Interest: None declared.

References

1. Chua KJ, Kwok WC, Aggarwal N, Sun T, Chang MW. Designer probiotics for the prevention and treatment of human diseases. Curr Opin Chem Biol. 2017;40:8-16. doi: 10.1016/j.cbpa.2017.04.011. PubMed PMID: 28478369.
2. Hemarajata P, Versalovic J. Effects of probiotics on gut microbiota: mechanisms of intestinal immunomodulation and neuromodulation. Therap Adv Gastroenterol. 2013;6:39-51. doi: 10.1177/1756283X12459294. PubMed PMID: 23320049; PubMed Central PMCID: PMCPMC3539293.
3. Fijan S. Microorganisms with claimed probiotic properties: an overview of recent literature. Int J Environ Res Public Health. 2014;11:4745-67. doi: 10.3390/ijerph11050474. PubMed PMID: 24859749; PubMed Central PMCID: PMCPMC4053917.
4. De Vrese M, Offick B. Probiotics and prebiotics: effects on diarrhea. Bioactive Foods in Promoting Health. New York: Elsevier; 2010. p. 205-27.
5. Ooi LG, Liong MT. Cholesterol-lowering effects of probiotics and prebiotics: an overview of in vivo and in vitro findings. Int J Mol Sci. 2010;11:2499-522. doi: 10.3390/ijms11062499. PubMed PMID: 20640165; PubMed Central PMCID: PMCPMC2904929.
6. Oak SJ, Jha R. The effects of probiotics in lactose intolerance: A systematic review. Crit Rev Food Sci Nutr. 2019;59:1675-83. doi: 10.1080/10408398.2018.1425977. PubMed PMID: 29425071.
7. Kopp MV, Saffeld P. Probiotics and prevention of allergic disease. Curr Opin Clin Nutr Metab Care. 2009;12:298-303. doi: 10.1097/
MCO.0b013e32832989a3. PubMed PMID: 19318939.
8 Sharif MK, Mahmood S, Ahsan F. Role of Probiotics Toward the Improvement of Gut Health With Special Reference to Colorectal Cancer. Diet, Microbiome and Health. New York: Elsevier; 2018. p. 35-50. doi: 10.1016/B978-0-12-811440-7.00002-8.
9 Dasari S, Kathera C, Janardhan A, Praveen Kumar A, Viswanath B. Surfacing role of probiotics in cancer prophylaxis and therapy: A systematic review. Clin Nutr. 2017;36:1465-72. doi: 10.1016/j.clnu.2016.11.017. PubMed PMID: 27923508.
10 So SS, Wan ML, El-Nezami H. Probiotics-mediated suppression of cancer. Curr Opin Oncol. 2017;29:62-72. doi: 10.1097/CCO.0000000000000342. PubMed PMID: 27772053.
11 Halper J, Leshin LS, Lewis SJ, Li WI. Wound healing and angiogenic properties of supernatants from Lactobacillus cultures. Exp Biol Med (Maywood). 2003;228:1329-37. doi: 10.1177/153537020322801111. PubMed PMID: 14681548.
12 Li WI, Brackett BG, Halper J. Culture supernatant of Lactobacillus acidophilus stimulates proliferation of embryonic cells. Exp Biol Med (Maywood). 2005;230:494-500. doi: 10.1177/153537020523000708. PubMed PMID: 15985625.
13 Samadikuchaksaraei A, Gholiourmalemakabadi M, Saberian M, Abdollahpour Aliatappeh M, Shahidi Delshad E. How does the supernatant of Lactobacillus acidophilus affect the proliferation and differentiation activities of rat bone marrow-derived stromal cells? Cell Mol Biol (Noisy-le-grand). 2016;62:1-6. PubMed PMID: 27609467. doi: 10.14715/cmb/2016.62.10.1.
14 Kolinska J, Zakostelecka M, Zemanova Z, Lisa V, Golias J, Kozakova H, et al. Cellular differentiation of non-transformed intestinal epithelial cells is regulated by Lactobacillus rhamnosus and L. casei strains. Physiol Res. 2018;67:261-73. doi: 10.33549/physiolres.933643. PubMed PMID: 29303613.
15 Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8:726-36. doi: 10.1038/nri2395. PubMed PMID: 19172693.
16 Le Blanc K, Samuelsson H, Gustafsson B, Remberger M, Sundberg B, Arvidson J, et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia. 2007;21:1733-8. doi: 10.1038/sj.leu.2404777. PubMed PMID: 17541394.
17 Pizon MA, McCarrle TM, Porter E, Kelleman A, Macpherson ML, Smith A. Technical aspects of mesenchymal stem cells transplantation into the stallion testes. Animal Reproduction Science. 2018;194:e8.
18 Marteau P, Pochart P, Flourié B, Pellier P, Santos L, Desjeux JF, et al. Effect of chronic ingestion of a fermented dairy product containing Lactobacillus acidophilus and Bifidobacterium bifidum on metabolic activities of the colonic flora in humans. Am J Clin Nutr. 1990;52:685-8. doi: 10.1093/ajcn/52.4.685. PubMed PMID: 2119557.
19 Khavari-Daneshvar H, Mosavi M, Khodayari H, Rahimi E, Ranji P, Mohseni AH, et al. Modifications of mice gut microflora following oral consumption of Lactobacillus acidophilus and Bifidobacterium bifidum probiotics. Turk J Med Sci. 2017;47:689-94. doi: 10.3906/sag-1504-28. PubMed PMID: 28425267.
20 Watson D, O’Connell Motherway M, Schoterman MH, van Neerwen RJ, Nauta A, van Sinderen D. Selective carbohydrate utilization by lactobacilli and bifidobacteria. J Appl Microbiol. 2013;114:1132-46. doi: 10.1111/jam.12105. PubMed PMID: 23240984.
21 Roy D. Media for the isolation and enumeration of bifidobacteria in dairy products. Int J Food Microbiol. 2001;69:167-82. doi: 10.1016/s0168-1605(01)00496-2. PubMed PMID: 11603854.
22 Pyar H, Peh K. Characterization and identification of Lactobacillus acidophilus using biolog rapid identification system. Int J Pharm Pharm Sci. 2014;6:189-93.
23 Piccinini F, Tesei A, Arienti C, Bevilacqua A. Cell Counting and Viability Assessment of 2D and 3D Cell Cultures: Expected Reliability of the Trypan Blue Assay. Biol Proced Online. 2017;19:8. doi: 10.1186/s12575-017-0056-3. PubMed PMID: 28814944; PubMed Central PMCID: PMCPMC5518102.
24 Soleimani M, Nadri S. A protocol for isolation and culture of mesenchymal stem cells from mouse bone marrow. Nat Protoc. 2009;4:102-6. doi: 10.1038/nprot.2008.221. PubMed PMID: 19131962.
25 Zhang Y, Khan D, Delling J, Tobiasch E. Mechanisms underlying the osteo- and adipodifferentiation of human mesenchymal stem cells. ScientificWorldJournal. 2012;2012:793823. doi: 10.1100/2012/793823. PubMed PMID: 22500143; PubMed Central PMCID: PMCPMC3317548.
26 Paul H, Reginato AJ, Schumacher HR. Alizarin red S staining as a screening test to detect calcium compounds in synovial fluid. Arthritis Rheum. 1983;26:191-200. doi: 10.1002/art.1780260211. PubMed PMID: 6186260.
27 Kinkel AD, Fernyhough ME, Helterline DL, Vierck JL, Oberg KS, Vance TJ, et al. Oil red-O stains non-adipogenic cells: a precautionary note. Cytotechnology. 2004;46:49-56. doi: 10.1007/s10616-004-3903-4. PubMed PMID: 19003258; PubMed Central PMCID: PMCPMC3449473.

28 Gholipourmalekabadi M, Mozafari M, Bandehpour M, Salehi M, Sameni M, Caicedo HH, et al. Optimization of nanofibrous silk fibroin scaffold as a delivery system for bone marrow adherent cells: in vitro and in vivo studies. Biotechnol Appl Biochem. 2015;62:785-94. doi: 10.1002/bab.1324. PubMed PMID: 25471678.

29 Russo F, Linsalata M, Orlando A. Probiotics against neoplastic transformation of gastric mucosa: effects on cell proliferation and polyamine metabolism. World J Gastroenterol. 2014;20:13258-72. doi: 10.3748/wjg.v20.i37.13258. PubMed PMID: 25309063; PubMed Central PMCID: PMCPMC4188884.

30 Hughes KR, Harnisch LC, Alcon-Giner C, Mitra S, Wright CJ, Ketskemety J, et al. Bifidobacterium breve reduces apoptotic epithelial cell shedding in an exopolysaccharide and MyD88-dependent manner. Open Biol. 2017;7. doi: 10.1098/rsob.160155. PubMed PMID: 28123052; PubMed Central PMCID: PMCPMC5303268.

31 Saberian M, Shahidi Delshad E, Naji T, Samadikuchaksaraei A. Comparing The Effect Of Lactobacillus Acidophilus And MRS Medium On Mesenchymal Stem Cells Proliferation. Journal of Payavard Salamat. 2015;9:276-87. Persian.

32 Li WI, Brackett BG, Halper J. Culture supernatant of Lactobacillus acidophilus stimulates proliferation of embryonic cells. Exp Biol Med (Maywood). 2005;230:494-500. doi: 10.1177/153537020523000708. PubMed PMID: 15985625.

33 Halper J, Leshin LS, Lewis SJ, Li WI. Wound healing and angiogenic properties of supernatants from Lactobacillus cultures. Exp Biol Med (Maywood). 2003;228:1329-37. doi: 10.1177/153537020322801111. PubMed PMID: 14681548.

34 Wagner W, Horn P, Castoldi M, Diehlmann A, Bork S, Saffrich R, et al. Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS One. 2008;3:e2213. doi: 10.1371/journal.pone.0002213. PubMed PMID: 18493317; PubMed Central PMCID: PMCPMC2374903.